You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 295 No. 23, June 21, 2006 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Oncology
 •Breast Cancer
 •Adverse Effects
 •Alert me on articles by topic

Statins and the Risk of Cancer—Reply

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: Dr Duncan and colleagues raise questions about the categorization of hydrophilicity and lipophilicity in the subgroup analysis. There are 3 levels of lipophilicity for statins. Pravastatin and rosuvastatin have low lipophilicity, atorvastatin and fluvastatin have modest lipophilicity, and simvastatin and lovastatin have high lipophilicity.1 Pravastatin, fluvastatin, and atorvastatin do not penetrate the blood-brain barrier.2 From postmarketing surveillance, the risk of death from rhabdomyolysis is quite similar between pravastatin, fluvastatin, and atorvastatin, but lower than that of simvastatin and lovastatin.3 We therefore believe that fluvastatin and atorvastatin act more like hydrophilic agents than lipophilic ones. However, when we analyzed pravastatin alone for breast cancer incidence, the results (odds ratio [OR], 1.38; 95% confidence interval [CI], 0.72-2.65) were similar to our overall statin findings, as they were for colon, gastrointestinal, and respiratory cancer incidence. Pravastatin therefore does not appear to exhibit procancer effects that might have countered the anticancer effects . . . [Full Text of this Article]

Krista Dale, PharmD; C. Michael White, PharmD
cmwhite@harthosp.org
Drug Information Center
University of Connecticut
Storrs


RELATED ARTICLES

Statins and the Risk of Cancer
Robin E. Duncan, Ahmed El-Sohemy, and Michael C. Archer
JAMA. 2006;295(23):2720.
EXTRACT | FULL TEXT  

Statins and the Risk of Cancer
Michael R. Freeman, Keith R. Solomon, and Mark Moyad
JAMA. 2006;295(23):2720-2721.
EXTRACT | FULL TEXT  

Statins and the Risk of Cancer
Claudia A. Salinas, Ilir Agalliu, Janet L. Stanford, and Daniel W. Lin
JAMA. 2006;295(23):2721.
EXTRACT | FULL TEXT  

Statins and Cancer Risk: A Meta-analysis
Krista M. Dale, Craig I. Coleman, Nickole N. Henyan, Jeffrey Kluger, and C. Michael White
JAMA. 2006;295(1):74-80.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.